Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117) [3]

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 805-

  Fiorentini, G ^a   Rossi, S ^a   Lanzanova, G ^b   Bernardeschi, P ^a   Dentico, P ^a   De Giorgi, U ^b  

^a SAN GIUSEPPE HOSPITAL   (Italy)

^b SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CISPLATIN; FOTEMUSTINE; IMATINIB; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; TYROSINE KINASE RECEPTOR;

ADULT; AGED; CANCER PALLIATIVE THERAPY; CASE REPORT; DIARRHEA; DIMERIZATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; EYE CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; LIPOSARCOMA; MALE; MELANOMA; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; RETROPERITONEAL CANCER;

ADULT; AGED; EYE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; MELANOMA; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 0038443937     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg192     Document Type: Letter

References (5)

1. Majumder S, Brown K, Qiu FH et al. c-kit protein, a trans-membrane kinase. Identification in tissues and characterization. Mol Cell Biol 1988; 8: 4896-4903.
2. Blume-Jensen P, Claesson-Welsh L, Siegbahn A et al. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 1991; 10: 4121-4128.
3. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997; 1333: F217-F248.
4. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukaemia. J Clin Invest 2000; 105: 3-7.
5. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121.